Wolfgang Miesbach: FRONTIER4 Long-Term Results Highlight the Promise of Denecimig in Haemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”FRONTIER4 — denecimig (Mim8) long-term data presented at ISTH 2026 in Paris.
Among the clinically relevant prophylaxis updates, OC 02.4 by Jerzy Windyga reported interim safety and efficacy results from FRONTIER4, the long-term extension study of the denecimig (Mim8) programme in haemophilia A.
Denecimig is a next-generation subcutaneous FVIIIa mimetic, optimised for FIXa cofactor activity and thrombin generation.
What sets the programme apart is the dosing flexibility: once weekly, once every two weeks, or once monthly — by patient choice after week 26.
Interim analysis in adults and adolescents (≥12 years, N=365; median observation ~0.5 years):
Efficacy
- Overall estimated mean ABR 0.75, consistently low across all three schedules (QW 0.91, Q2W 0.55, QM 0.74)
- Median observed ABR was zero in every subgroup
- 71.2% with zero treated bleeds
- Low spontaneous bleeds (ABR 0.09) and near-absent target-joint bleeds (ABR 0.01, 97% zero)
- Low ABRs irrespective of FVIII inhibitor status (positive 0.15, negative 0.88)
Safety
- No thromboembolic events
- Injection-site reactions in 1.8% of injections (108/6138); the majority of AEs mild
- No clinical evidence of neutralising anti-denecimig antibodies
Monthly dosing maintained bleed protection comparable to weekly — a genuine opportunity to reduce treatment burden, with low bleed rates holding regardless of inhibitor status.
Congratulations to the investigators and, above all, to the FRONTIER4 participants.”
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community